ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- High Expression of GPR183 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia.Biochemical genetics · 2026Article
- What is new in acute myeloid leukemia classification?Blood research · 2024Review
- Expression analysis, clinical significance and potential function of PLXNB2 in acute myeloid leukaemia.Molecular biology reports · 2023Article
- Early response evaluation by single cell signaling profiling in acute myeloid leukemia.Nature communications · 2023Article
- Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia.Cancer pathogenesis and therapy · 2023Article
- Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?Haematologica · 2022Article
- Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.Blood advances · 2022Article
- Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.Blood advances · 2022Article
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.Blood cancer journal · 2021Article
- Article
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.Clinical lymphoma, myeloma & leukemia · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.